Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria

By Public Technologies
  • Vertex reported positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease across two patient cohorts.
  • Treatment reduced protein in urine in patients with modest proteinuria, supporting potential use beyond the earlier focal segmental glomerulosclerosis population.
  • Patients with type 2 diabetes saw a smaller improvement, suggesting a more variable response in that subgroup.
  • Safety profile was generally favorable, with no drug-related serious adverse events reported.
  • Enrollment finished in the Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921995768) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.